Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. - Wikidata - awgldk - TriplyDB

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

http://www.wikidata.org/entity/Q34874626

about

Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysis Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care Cryptococcus-Related Immune Reconstitution Inflammatory Syndrome (IRIS): Pathogenesis and its Clinical Implications Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal Integrated therapy for HIV and cryptococcosis HIV-Associated Cryptococcal Meningitis: Bridging the Gap Between Developed and Resource-Limited Settings A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi A Population Genomics Approach to Assessing the Genetic Basis of Within-Host Microevolution Underlying Recurrent Cryptococcal Meningitis Infection.Neuromeningeal cryptococcosis in sub-Saharan Africa: Killer disease with sparse data Treatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi Cryptococcal meningitis: epidemiology and therapeutic options.Clinical pharmacokinetics of oral controlled-release 5-fluorocytosine Optimum timing of antiretroviral therapy for HIV-infected patients with concurrent serious opportunistic infections.Cryptococcal meningitis: A neglected NTD?Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients Comparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplant A prospective study of mortality from cryptococcal meningitis following treatment induction with 1200 mg oral fluconazole in Blantyre, Malawi.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions An update on Cryptococcus among HIV-infected patients.Neurologic complications of HIV disease and their treatment.MORTALITY AFTER CLINICAL MANAGEMENT OF AIDS-ASSOCIATED CRYPTOCOCCAL MENINGITIS IN KENYA.Combination Versus Monotherapy for the Treatment of HIV Associated Cryptococcal Meningitis Cryptococcosis diagnosis and treatment: What do we know now Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.Comparative effectiveness of induction therapy for human immunodeficiency virus-associated cryptococcal meningitis: a network meta-analysis.AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial.Predictors of dropout from care among HIV-infected patients initiating antiretroviral therapy at a public sector HIV treatment clinic in sub-Saharan Africa.Cryptococcal Meningitis: Diagnosis and Management Update.Role of quantitative CSF microscopy to predict culture status and outcome in HIV-associated cryptococcal meningitis in a Brazilian cohort.Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.Factors associated with early mycological clearance in HIV-associated cryptococcal meningitis Cerebrospinal Fluid Culture Positivity and Clinical Outcomes After Amphotericin-Based Induction Therapy for Cryptococcal Meningitis.The prevalence, clinical features, risk factors and outcome associated with cryptococcal meningitis in HIV positive patients in Kenya.

P2860

Q21144604-78B6DEB4-52C6-43BF-8998-25FCA99BEE9C Q24600270-EBAD0828-24CC-4574-8552-06A7219D6EBE Q24610933-66BA7DD8-CDCC-4450-92C7-19B7E74328D5 Q24629367-D7898B32-E8FA-4F53-92EC-78ECBF5E05E6 Q24630287-8476ADB9-CE24-46DA-A706-B5C2D35120B4 Q27012487-BC84909C-39F4-49D5-9CC1-2A9487F4160E Q28077707-987822C6-4400-4BAC-890D-8167656C5F0E Q28078958-DF51563A-116F-42DF-89C4-060F1F377228 Q28534417-CB377C38-04EB-4D89-95CB-E54768165E79 Q30844823-DEAB8E75-6E17-404E-86DD-5922935CEE43 Q30934853-DCD306D0-07BB-4FCB-8FEE-1F869B6E841C Q33523050-A4285C79-8CE1-41F4-B04A-91860FC4E2D4 Q33532335-988F82AF-760B-4D13-8C4F-D73AA1B96320 Q33588561-811BCC50-9CA2-448E-8617-8CC1844A27DB Q33633343-C8128773-179A-4B0B-873B-2329E24BB729 Q33676182-9158B710-0B9D-475B-B7EA-FDC17D1379F3 Q33823233-915ED7C1-9B9C-4326-9055-9E6B1732A98E Q33852819-86B711F9-F9CE-44F1-91E2-B158DFB67DC6 Q33982933-71607638-E5DD-4C73-94A5-70EFC6967854 Q34020746-F4AEB087-0243-496C-A3E7-8E01926B4732 Q34024416-6EC27ED0-E726-45F4-BF6F-45EA9EBDEACA Q34247688-28896FB1-04B5-410C-BDBD-7F67053705A2 Q34399223-CEFF2343-801A-4E2E-9A00-4816D6ACC307 Q34465185-4CDBC6F5-7ED5-4FFC-A978-104C19F3404C Q34516548-7B694C97-C95C-4C45-84B7-29E1C72FFEF8 Q34625655-200314EC-7005-487C-9A4C-B1D95C46CD42 Q34730716-ECF2E4FE-A69C-4961-9B69-AFB1354BFFBA Q35073767-A4B1C30B-15EE-4CD3-A818-BFB00D813939 Q35230534-98E43F50-98BB-4043-86FD-0C4D56748F35 Q35395169-91BA2B15-DB4E-494C-BE44-418D495263F2 Q35396977-AE95612D-4A1A-4783-BF41-DE32787BC8F7 Q35628245-2D7DB37E-F7D7-4872-A7BC-60EEFF3B5808 Q35776693-6351665A-B781-430A-8242-5FB804E87F22 Q35911192-9E60CA7A-3921-4298-954B-BEBC4DACD5DD Q35951094-11B60A75-43C8-4D4E-B0F5-33A2A1972577 Q35957939-9114FB20-42AB-468E-A764-162CAEC8EEBD Q36290696-CD8D2FB4-FA6A-4E91-8D8E-C2A5E6A89BCE Q36326762-BEA4B80A-D22F-40ED-A8A3-BF7FA87F5CD0 Q36407524-B6CAC4BB-D3C7-44FB-B760-D232C0DA09DB Q36700649-24F521B3-B97A-4E8D-AAB6-64B411EB407C

P2860

Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda.

http://www.wikidata.org/entity/Q34874626

description

2008 nî lūn-bûn

@nan

2008 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@ast

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@en

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@nl

type

label

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@ast

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@en

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@nl

prefLabel

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@ast

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@en

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@nl

P1433

Q34874626-663360AE-CA3A-451C-B1A5-3820F544C055

P1476

Q34874626-B5FAE749-42D8-4176-9BAA-F793B0E6EF03

P2093

Q34874626-16F7D52E-9CBD-42CA-A4E3-17B96D615FC5

Q34874626-33C29BDD-152D-4096-81FE-1749E59EB42E

Q34874626-344CB838-632F-4EB8-A33F-22A7C4200CD8

Q34874626-6861E360-5D98-4F50-B4C4-588262C8E852

Q34874626-68EAA708-6779-412D-ADA3-EEA252ED2B48

Q34874626-7367252A-D8A3-4E65-9042-A69952E1931E

Q34874626-F1296B96-EABD-47B4-B0A0-89AD4FBFA3A9

P2860

Q34874626-10BCB70F-85C1-449C-84AF-AE3AF1D095B8

Q34874626-1806C409-5F70-4E76-A031-74B9657C5E9B

Q34874626-1DF46634-3921-4979-97AB-57D3032BCA21

Q34874626-228D2402-DAAA-4BBF-8C67-E21114C4C058

Q34874626-24712570-AEB8-4C1F-AC9D-17AE5B062E6E

Q34874626-2844C6B5-1C50-4E48-B7E7-9966C948C59C

Q34874626-4823E05D-2509-4661-A7C2-F782758AB839

Q34874626-4CE3B306-3E1B-40E4-BF99-D20E88D5FB20

Q34874626-4E37956A-3EAB-430F-89FA-389E5441A29E

Q34874626-5EACE687-02CB-4710-9389-BC26F84A7CF1

P304

Q34874626-78AC9173-5866-4A7E-A57E-FB7ADAC715F3

P31

Q34874626-D0143619-1A68-4B60-A087-1DF981DB912F

P356

Q34874626-3FB94BC3-09D1-42FB-B69A-65AC3BECCA05

P407

Q34874626-7969B23B-B246-4E0F-893B-333B4B5B7AEA

P433

Q34874626-7CFB85D3-8DC1-45D2-AF45-1F343CEAB5C8

P478

Q34874626-F91335F1-B26F-46A1-9314-E612F9695128

P50

Q34874626-087E8556-70E1-4C91-B7E7-91B6B6B4485D

Q34874626-339C1F2D-757F-4B8F-A9C2-21D9F8BFE3AD

Q34874626-C7763004-7867-4EE2-9EA6-65B739C9CBD6

P577

Q34874626-CA8F60C6-D979-4E12-841F-C7C76EC755A7

P5875

Q34874626-569A58D9-F3CD-4BB1-A7DB-7B2D4F4CD455

P698

Q34874626-C8518345-3C0F-43D7-9F9E-2C67D552841A

P921

Q34874626-D86B24CA-B144-46C7-B15A-DDCAED9D1FA3

Q34874626-FD70F44D-F250-4CEC-B5CE-DD4FEF736FB7

P356

P1433

Clinical Infectious Diseases

P1476

Dose response effect of high-d ...... ngitis in southwestern Uganda.

@en

P2093

Ali Chakera

http://www.w3.org/2001/XMLSchema#string

Conrad Muzoora

http://www.w3.org/2001/XMLSchema#string

Irene Andia

http://www.w3.org/2001/XMLSchema#string

James Mwesigye

http://www.w3.org/2001/XMLSchema#string

Joselyne Rwebembera

http://www.w3.org/2001/XMLSchema#string

Kabanda Taseera

http://www.w3.org/2001/XMLSchema#string

Nicky Longley

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions

Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole.

High-dose fluconazole therapy in patients with severe fungal infections.

Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.

Coccidioidal meningitis.

Pharmacokinetics and pharmacodynamics of antifungals.

Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.

The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes.

Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

P304

1556-1561

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/593194

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Harrison

P577

2008-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23457271

http://www.w3.org/2001/XMLSchema#string

P698

18990067

http://www.w3.org/2001/XMLSchema#string

P921